NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
Clinical Trials
59 trialsNCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT04895436 2026-02-09
ReVenG
AbbVie
Phase 2 Recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT05466994 2026-01-15
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03467867 2025-12-24
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
Phase 2 Active not recruiting
NCT06510699 2025-11-19
PRAGMATIC
The University of Queensland
Phase 2 Recruiting
NCT03680092 2025-10-02
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
University of California, San Diego
Phase 2 Completed
NCT06482515 2025-07-03
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
University of Maryland, Baltimore
Phase 2 Recruiting
NCT06862323 2025-06-13
Time Restricted Eating in Haematological Malignancies
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT04996875 2025-05-30
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT02494258 2025-05-22
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT02566304 2025-04-24
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT06351306 2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2 Withdrawn
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT01611142 2024-06-17
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00019097 2024-03-04
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT05100316 2024-02-05
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
GlaxoSmithKline
Phase 2 Terminated
NCT04956666 2023-12-29
ALL
Servier
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT04954326 2023-07-12
ALL
Servier
Phase 2 Completed
NCT05291390 2022-11-29
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Armaceutica, Inc.
Phase 2 Unknown
NCT01462578 2021-11-15
RELAZA2
Technische Universität Dresden
Phase 2 Completed
NCT00495079 2021-03-05
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT04016116 2020-05-27
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
NYU Langone Health
Phase 2 Withdrawn
NCT01012492 2019-11-21
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
Boston Children's Hospital
Phase 2 Completed
NCT00276159 2019-09-04
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01162551 2019-08-06
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Children's Hospital of Philadelphia
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT01531894 2019-07-09
Continuation Study of the Oral AKT Inhibitor GSK2110183
Novartis
Phase 2 Completed
NCT02258529 2019-05-14
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
Phase 2 Terminated
NCT01833169 2018-10-19
SIGNATURE
Novartis
Phase 2 Completed
NCT02371590 2018-02-23
Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
Phase 2 Withdrawn
NCT00077922 2018-01-23
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00617929 2017-12-28
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00607997 2017-06-28
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
Phase 2 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT01036009 2016-06-23
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
University of California, San Francisco
Phase 2 Completed
NCT00582933 2016-02-01
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00731328 2015-12-31
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Asan Medical Center
Phase 2 Completed
NCT01062230 2015-04-06
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
University of Arkansas
Phase 2 Terminated
NCT00290472 2014-05-23
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01035502 2013-09-27
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Clavis Pharma
Phase 2 Completed
NCT00637637 2013-08-12
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00795886 2013-07-31
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)
University of Utah
Phase 2 Completed
NCT00410696 2013-07-01
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
Istituto Clinico Humanitas
Phase 2 Completed
NCT01095926 2013-06-28
Doxo
University Hospital Muenster
Phase 2 Completed
NCT00514696 2013-06-17
PR-CS008
La Jolla Pharmaceutical Company
Phase 2 Completed